Literature DB >> 10780514

Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG).

I J Diel1, G R Mundy.   

Abstract

Several animal models, as well as a number of cell culture experiments, indicate a prophylactic effect of bisphosphonates in respect of subsequent bone metastasis. Moreover, in preliminary clinical trials involving patients with advanced breast cancer and local or remote metastases, biophosphonates produced a reduction in new skeletal metastases. This overview summarizes and discusses the results of the latest investigations. It opens with a section on the pathophysiology of bone metastasis, which is followed by a report on animal models and first studies of bisphosphonate treatment as a new approach in systemic adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780514      PMCID: PMC2363374          DOI: 10.1054/bjoc.1999.1077

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  51 in total

1.  Influence of clodronate on breast cancer cells in vitro.

Authors:  M Busch; M Rave-Fränk; A Hille; E Dühmke
Journal:  Eur J Med Res       Date:  1998-09-17       Impact factor: 2.175

Review 2.  Bisphosphonates: mechanisms of action.

Authors:  G A Rodan; H A Fleisch
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

3.  Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.

Authors:  H L Benford; J C Frith; S Auriola; J Mönkkönen; M J Rogers
Journal:  Mol Pharmacol       Date:  1999-07       Impact factor: 4.436

4.  The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.

Authors:  C M Shipman; P I Croucher; R G Russell; M H Helfrich; M J Rogers
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

5.  Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro.

Authors:  J Mönkkönen; M Taskinen; S O Auriola; A Urtti
Journal:  J Drug Target       Date:  1994       Impact factor: 5.121

Review 6.  Bone and cancer: pathophysiology and treatment of metastases.

Authors:  J A Kanis
Journal:  Bone       Date:  1995-08       Impact factor: 4.398

7.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

Authors:  J R Berenson; A Lichtenstein; L Porter; M A Dimopoulos; R Bordoni; S George; A Lipton; A Keller; O Ballester; M J Kovacs; H A Blacklock; R Bell; J Simeone; D J Reitsma; M Heffernan; J Seaman; R D Knight
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

8.  Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.

Authors:  D E Hughes; K R Wright; H L Uy; A Sasaki; T Yoneda; G D Roodman; G R Mundy; B F Boyce
Journal:  J Bone Miner Res       Date:  1995-10       Impact factor: 6.741

9.  Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system.

Authors:  D G Hall; G Stoica
Journal:  J Bone Miner Res       Date:  1994-02       Impact factor: 6.741

10.  Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.

Authors:  A Sasaki; B F Boyce; B Story; K R Wright; M Chapman; R Boyce; G R Mundy; T Yoneda
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

View more
  5 in total

1.  Roles of osteoclasts and bone-derived IGFs in the survival and growth of human breast cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.

Authors:  Takafumi Sangai; Hiroshi Fujimoto; Shin'ichi Miyamoto; Hiroyuki Maeda; Michio Nakamura; Genichiro Ishii; Kanji Nagai; Takeshi Nagashima; Masaru Miyazaki; Atsushi Ochiai
Journal:  Clin Exp Metastasis       Date:  2008-02-29       Impact factor: 5.150

2.  Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma.

Authors:  Agustin Avilés; María J Nambo; Natividad Neri; Claudia Castañeda; Sergio Cleto; Judith Huerta-Guzmán
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.

Authors:  Jouko Sandholm; Jaakko Lehtimäki; Tamiko Ishizu; Sadanandan E Velu; Jeremy Clark; Pirkko Härkönen; Arja Jukkola-Vuorinen; Aleksi Schrey; Kevin W Harris; Johanna M Tuomela; Katri S Selander
Journal:  Oncotarget       Date:  2016-12-27

4.  Isolated distal ulnar bone metastasis from lung squamous cell carcinoma: an extremely rare case report.

Authors:  Kuei-Lin Yeh; Szu-Hsien Wu; Shing-Sheng Wu
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

5.  10. Circulating Nucleic Acids as Diagnostic Tool.

Authors:  Maurizio Ferrari; Laura Cremonesi; Silvia Galbiati
Journal:  EJIFCC       Date:  2008-04-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.